The impact of Pegylated liposomal doxorubicin in recurrent ovarian cancer: an updated meta-analysis of randomized clinical trials

BACKGROUND: Previous meta-analysis studies suggested that pegylated liposomal doxorubicin (PLD) may improve the survival rate of patients with recurrent ovarian cancer. The aim of the present meta-analysis, then, was to further update the role of PLD in the treatment of recurrent ovarian cancer. MET...

Descripción completa

Detalles Bibliográficos
Autores principales: Li, Xin-Ru, Zhu, Yi, Zhang, Guo-Nan, Huang, Jian-Ming, Pei, Li-Xia
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2021
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7945320/
https://www.ncbi.nlm.nih.gov/pubmed/33750444
http://dx.doi.org/10.1186/s13048-021-00790-4

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7945320/
https://www.ncbi.nlm.nih.gov/pubmed/33750444
http://dx.doi.org/10.1186/s13048-021-00790-4

Ejemplares similares